- Home
- ABVC vs ALGS Comparison
ABVC vs ALGS Comparison
Compare ABVC & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABVC | ALGS |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 33.0M |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ABVC | ALGS |
|---|---|---|
| Price | $1.49 | $5.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | ★ 115.9K | 83.9K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.14 | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | $509,589.00 | ★ $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.88 | $4.80 |
| 52 Week High | $4.02 | $13.69 |
Technical Indicators
Market Signals| Indicator | ABVC | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 64.59 | 48.70 |
| Support Level | $1.00 | $4.80 |
| Resistance Level | $1.71 | $6.82 |
| Average True Range (ATR) | 0.11 | 0.36 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 76.87 | 55.34 |
Price Performance
Historical ComparisonAbout ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.